T-VEC may support immunotherapy by enhanced by IFNγ and TNFα production, which can increase PD-L1 expression, promote influx of effector CD8+ T cell to the tumor microenvironment and decrease the number of CD4 + FoxP3+ regulatory T cells [22]. The gene discussed is CD4; the disease is neoplasm.